Drug Pipeline News

Elinzanetant, a non-hormonal drug, shows promising results in reducing hot flashes and night sweats, offering a new option for women seeking effective and safe treatment for vasomotor symptoms.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The New Drug Application (NDA) acceptance is supported by positive data from 3 clinical trials (OASIS 1, 2, and 3).

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

The phase 3 OASIS trial presented at the 2024 Annual Meeting of The Menopause Society displayed significant improvements in the frequency of moderate-to-severe vasomotor symptoms among patients receiving elinzanetant.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The advisory committee meeting will discuss the potential approval of oral sulopenem etzadroxil/probenecid tablets for treating urinary tract infections in women aged 18 years and older.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Astellas Pharma has announced the first dose administration of fezolinetant to manage moderate to severe vasomotor symptoms in breast cancer patients using adjuvant endocrine therapy.

In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.

The investigational drug could prevent the rare fetal disease HDFN (hemolytic disease of the fetus and newborn) by stopping harmful antibodies from transferring through the placenta during pregnancy.

The over-the-counter, at-home test provides blood results in 15 minutes that could help result in sooner syphilis diagnoses.

A year after zuranolone’s FDA approval for postpartum depression on August 3, 2023, prescribers and a patient weigh in about the medication’s success in alleviating symptoms.

Bayer has submitted a New Drug Application for elinzanetant, following positive results from the OASIS studies, showing significant safety and efficacy in treating moderate-to-severe vasomotor symptoms in menopausal women.

These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.

Femlyv, containing norethindrone acetate and ethinyl estradiol, offers a new oral contraceptive option for individuals with swallowing difficulties, expanding access and convenience.

Reunion Neuroscience Inc. initiates phase 2 trial of RE104, a novel short-duration psychedelic treatment for postpartum depression, aiming to provide rapid and effective relief for affected mothers.

Serac Healthcare’s 99mTc-maraciclatide, a new radio-labelled tracer, gains FDA Fast Track Designation for its potential to improve non-invasive diagnosis of superficial peritoneal endometriosis in patients aged 16 and older.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a unanimous ruling, the Supreme Court rejected a challenge by antiabortion doctors, maintaining nationwide access to mifepristone for medication abortions and reversing a lower court's decision to restrict the pill's availability.

Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.

Explore the efficacy of Pivya (pivmecillinam; Utility Therapeutics) tablets in managing uncomplicated urinary tract infections in female adults, supported by controlled clinical trials and safety considerations.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.